Trial Profile

Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Liver metastases
Focus Therapeutic Use

30 Jan 2024 Planned number of patients changed from 45 to 355.
15 Jun 2020 A pooled analysis of five prospective trials; results published in the European Journal of Cancer
13 Mar 2018 Results of a pooled analysis of five prospective trials ((NCT00719797, NCT02271464, NCT02295930, EudraCT2008-001062-93 and NCT02086656; n=153) assessing prognostic impact of histopathologic parameters, published in the British Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com